ReviewCureus2026
Diagnostic and Prognostic Value of Serum Surfactant Protein D in Interstitial Lung Disease: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum surfactant protein D (SP-D), secreted by alveolar type II pneumocytes, leaks into the circulation during alveolar epithelial injury, making it a candidate biomarker for interstitial lung disease (ILD). This systematic review appraises its contemporary diagnostic and prognostic value across ILD subtypes. PubMed, Scopus, Web of Science, and Embase were searched for original studies published from 2021 to 2025 reporting serum SP-D in adult ILD patients. Study selection, data extraction, and quality assessment (Newcastle-Ottawa Scale) followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Narrative synthesis was performed because of heterogeneity in populations, assay platforms, and outcomes. Ten studies enrolling 4,179 participants were included. Serum SP-D was significantly elevated in ILD versus controls in most studies, with diagnostic area under the curve values of 0.65-0.89. It correlated with forced vital capacity, diffusing capacity of the lungs for carbon monoxide, and radiological extent across phenotypes, and independently predicted progression in rheumatoid arthritis-associated ILD (hazard ratio = 1.003; p = 0.008). In acute exacerbation, SP-D uniquely correlated with coagulation markers, suggesting a distinct pathobiological role not captured by Krebs von den Lungen-6 (KL-6). Prognostic utility was limited in antifibrotic-treated idiopathic pulmonary fibrosis. KL-6 outperformed SP-D as a standalone marker, but SP-D provided complementary, non-redundant value in multi-biomarker strategies. Serum SP-D is a clinically relevant biomarker of alveolar injury in ILD, best utilised within multi-marker panels. Assay standardisation and prospective validation of SP-D-inclusive biomarker strategies remain priorities for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.